Table 1. Progression-free survival (PFS) and overall survival (OS) according to microvessel density and miRNA expression in tumor tissue.
| Median PFS (days) | p-value1 | Median OS (days) | p-value1 | |||
| HR (95% CI) | HR (95% CI) | |||||
| MVD | high2 | low2 | high2 | low2 | ||
| All patients | 75 | 213 | <0.0001 | 120 | NR | <0.0001 |
| 7.23 (3.47–15.07) | 6.27 (2.90–13.53) | |||||
| ADC | 83 | 270 | 0.0004 | 126 | NR | 0.071 |
| 10.44 (2.86–38.13) | 3.12 (0.91–10.70) | |||||
| SCC | 62.5 | 210.5 | <0.0001 | 118.5 | NR | <0.0001 |
| 6.81 (2.75–16.88) | 9.58 (3.57–25.73) | |||||
Footnote: MVD: microvessel density; ADC: lung adenocarcinoma; SCC: squamous cell lung cancer; PFS: progression-free survival; OS: overall survival; NR: not reached due to 1 year observation time; HR: hazard ratio; CI: confidence interval.
1
Log-rank test;
2
groups with high/low MVD or high/low expression for selected miRNAs according to cut-off values (median MVD or median relative expression).